智通财经APP获悉，港股恒生指数跌1.21%，跌267点，报21805点；恒生科技指数跌2.04%。港股早盘成交1222亿港元。
恒生生物科技指数逆市上涨，机构看好创新药出海及部分生物药公司国产替代。康方生物（09926）涨5.8%；信达生物（01801）涨4.47%；方舟健客（6086）涨超22%。
一脉阳光(02522)涨超6%，CT胸部病变标注数据正式通过上海数据交易所合规审核并成功上架。
堃博医疗-B(02216)再涨超13%，月内股价实现翻倍，核心产品BroncAblate智衡在中国获批上市。
基石药业-B(02616)早盘涨2%，旗下5项最新研究成果即将亮相AACR年会。
宜明昂科-B(01541)涨5%，MC-003/IMM72临床试验申请获国家药监局受理。
荣昌生物(09995)涨超8%，维迪西妥单抗一线治疗胃癌结果入选2025 ASCO口头报告。
国华(00370)再涨超9%，公司携手达闼成立港仔机器人，发展人形机器人产业生态。
易鑫集团(02858)涨8%，公司将于年内推出汽车金融行业首个Agentic大模型。
上美股份(02145)涨超6%创新高，拟成立合资公司打造新品牌，主力品牌韩束增长势能强劲。
百威亚太(01876)跌2.6%，公司短期业绩或因改革阵痛与外部冲击承压，25年或为战略调整期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.